Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarrs Group Regulatory News (CARR)

Share Price Information for Carrs Group (CARR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 129.50
Bid: 127.00
Ask: 132.00
Change: 4.00 (3.19%)
Spread: 5.00 (3.937%)
Open: 127.00
High: 132.00
Low: 127.00
Prev. Close: 125.50
CARR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Animax Limited

21 Sep 2018 07:00

RNS Number : 4794B
Carr's Group PLC
21 September 2018
 

 

 

 

 

 

CARR'S GROUP PLC ("Carr's" or the "Group")

Acquisition of Animax Limited

Carr's Group bolsters its position in animal health with key acquisition

 

 

21 September 2018: Carr's (CARR.L), the Agriculture and Engineering Group, announces the acquisition of the entire issued share capital of Animax Limited ("Animax"), a producer of market-leading animal health products, for a total cash consideration of up to £8.5m.

 

Animax, based in Suffolk in the UK, was established in 1982. The business specialises in the research, development and manufacture of highly effective animal health products. Animax is at the forefront of innovation in the field of livestock trace element supplementation. Its patent-protected leaching boluses, currently sold in the UK and overseas under the Tracesure® and Allsure® brands, are specifically designed to deliver health benefits to livestock consistently over prolonged periods.

 

Animax also produces other leading animal health and trace element supplementation products sold under well-known brands including Copasure®, Copinox®, Coprac®, Easycal®, Pardevit® and Paracide®.

 

Highlights and strategic rationale of the acquisition:

 

The acquisition of Animax aligns with the Group's stated strategy of investing in growing agriculture markets in the UK and internationally.

 

In particular, Animax and its product ranges:

 

· enhance the Group's position in the global animal health and livestock supplementation markets;

· bring innovation and patent-protected technology to the Group together with a number of recognised and highly respected brands;

· are highly complementary to, and will benefit from clear synergies with, the established Carr's Group feed block business across the USA, NZ, Europe, UK and Ireland; and

· broaden the Group's animal health and supplementation product ranges which bring added value to farmers.

 

Carr's will support the growth and development of Animax through investment in research to develop new products and by investing in manufacturing efficiencies. In addition, Carr's expects significant manufacturing, distribution and sales synergy benefits to be realised as a result of the acquisition.

 

As part of the acquisition, Carr's has also acquired the entire issued share capital of Animax's related party, Clinimax Limited ("Clinimax"). Clinimax is a manufacturer of specialist disinfectant products for use in the medical industry and which also carry the benefit of patent-protection.

 

Both businesses are being acquired for an initial cash consideration of £6m, with an additional cash consideration of up to a maximum of £2.5m payable over the period to November 2020, based on the achievement of agreed financial targets.

 

For the year ended 30 November 2017, Animax and Clinimax in aggregate recorded EBITDA of £0.6m and profit before tax of £0.3m. The combined gross assets of Animax and Clinimax as at 30 November 2017 totalled £5.6m, including cash of £1.2m. The acquisition is expected to be earnings enhancing in the first full year of ownership. The total consideration is being satisfied by the Group's existing facilities.

 

Tim Davies, Chief Executive, commented:

 

"We are delighted to announce the acquisition of Animax. This acquisition is in line with our stated strategy of developing our offering in the growing livestock specialist nutrition market both in the UK and internationally. Animax is highly complementary to our global feed block business and will add value to our customers' businesses. Animax has a history of developing market leading products based on sound research with their brands being recognised for their efficacy and performance. The combination of Carr's resources, knowledge and distribution, together with the Animax research capability, product technology and history of innovation, make a compelling case for this strategic step for the Group."

 

 

 

 

Enquiries:

Carr's Group plc

Tim Davies (Chief Executive)

Neil Austin (Group Finance Director)

 

Tel: +44 (0) 1228 554 600

Powerscourt

Nick Dibden / Lisa Kavanagh / Sam Austrums

 

Tel: +44 (0) 20 7250 1446

 

About Carr's Group plc:

Carr's is an international leader in manufacturing value added products and solutions, with market leading brands and robust market positions in Agriculture and Engineering, supplying customers in over 50 countries around the world.

Its Agriculture division manufactures and supplies feed blocks and supplementation products for livestock, distributes farm machinery and runs a UK network of rural stores, providing a one-stop shop for the farming community. Its Engineering division designs and manufactures bespoke equipment and provides technical engineering services into the nuclear, petrochemical, oil and gas, pharmaceutical, process and renewable energy industries, including robotic and remote handling equipment.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQGMGZLGGKGRZZ
Date   Source Headline
24th Apr 202410:31 amRNSReplacement: Strategic Update and Interim Results
18th Apr 20247:00 amRNSStrategic Update and Interim Results
15th Apr 202411:45 amRNSAppointment of Joint Corporate Broker
9th Apr 20247:00 amRNSTotal Voting Rights
7th Mar 202412:57 pmRNSTotal Voting Rights
22nd Feb 202412:40 pmRNSTotal Voting Rights
21st Feb 20242:58 pmRNSResult of Annual General Meeting 2024
31st Jan 20241:36 pmRNSBlocklisting Application
29th Jan 20249:48 amRNSDirector/PDMR Shareholding
24th Jan 20247:00 amRNSDirector/PDMR Shareholding
24th Jan 20247:00 amRNSDirector/PDMR Shareholding
16th Jan 202410:15 amRNSHolding(s) in Company
15th Jan 20243:13 pmRNSHolding(s) in Company
10th Jan 20245:29 pmRNSNotice of AGM 2024 and 2023 Annual Report
9th Jan 202412:43 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Jan 20247:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
27th Dec 20237:22 amRNSPublication of Annual Report and Accounts 2023
21st Dec 20237:00 amRNSFull Year Results
13th Dec 20231:03 pmRNSNotice of Results
13th Nov 20237:00 amRNSLeadership Changes and Notice of Results
1st Nov 20233:22 pmRNSOutcome of Shareholder Engagement
16th Oct 20232:13 pmRNSHolding(s) in Company
10th Oct 20237:00 amRNSTrading Update
6th Oct 20234:09 pmRNSNon-Executive Director Succession
2nd Oct 20239:44 amRNSHolding(s) in Company
31st Aug 20239:52 amRNSTotal Voting Rights
16th Aug 20234:24 pmRNSDirector/PDMR Shareholding
7th Aug 20237:00 amRNSCEO succession
4th Aug 20237:00 amRNSTrading Update
18th Jul 20239:07 amRNSHolding(s) in Company
7th Jul 20239:50 amRNSDirector/PDMR Shareholding
6th Jul 202312:40 pmRNSBLOCK LISTING SIX MONTHLY RETURN
6th Jul 202312:39 pmRNSBLOCK LISTING SIX MONTHLY RETURN
4th Jul 20234:48 pmRNSDirector/PDMR Shareholding
30th Jun 20239:44 amRNSTotal Voting Rights
13th Jun 202312:11 pmRNSHolding(s) in Company
31st May 20234:50 pmRNSTotal Voting Rights
23rd May 20231:01 pmRNSHolding(s) in Company
19th May 202312:57 pmRNSDirector/PDMR Shareholding
16th May 20231:32 pmRNSDirector/PDMR Shareholding
16th May 20239:20 amRNSDirector/PDMR Shareholding
5th May 20231:26 pmRNSDirector/PDMR Shareholding
5th May 20239:23 amRNSDirector/PDMR Shareholding
5th May 20239:22 amRNSDirector/PDMR Shareholding
4th May 20236:00 pmRNSReplacement: Holding(s) in Company
2nd May 20235:36 pmRNSReplacement: Total Voting Rights
2nd May 20233:09 pmRNSResult of General Meeting 2 May 2023
2nd May 202312:41 pmRNSHolding(s) in Company
2nd May 20237:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.